ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

aleniglipron

Also written as “Aleniglipron”, “GSBR-1290” and “GSBR-1290 (Capsule/Tablet)”.

Its studies are mostly in Obesity · Renal Insufficiency, led by Structure Therapeutics.

Drug pageAleniglipron: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 12, 20268 company-led studies, 5 open or runningNext primary completion: Mar 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Structure Therapeutics85 open or runningphase 3since Jun 12, 2026Jan 25, 2023Mar 2027phase 1 · NCT07946068

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 25, 2023First study: phase 2 study in OverweightFirst studyNCT05762471 · 142 enrolled · United States
  2. May 30, 2023Phase 1 study in Healthy VolunteersNCT05893043 · 18 enrolled · United States
  3. Nov 14, 2023Phase 1 study in Healthy VolunteersNCT06139055 · 70 enrolled · United States
  4. Aug 11, 2024Named aleniglipronINNProposed as its International Nonproprietary Name in WHO's List 131 · before, GSBR-1290
  5. Oct 28, 2025Phase 2 study in ObesityNCT07400588 · 58 enrolled · United States
  6. Jun 12, 20262 phase 3 studies in ObesityPhase 3 reachedNCT07654374, NCT07654361
  7. Oct 7, 2026Phase 1 study in Hepatic ImpairmentNCT07872033 · 36 planned · United States
  8. Nov 13, 2026Phase 1 study in Renal InsufficiencyNCT07946068 · 16 planned · United States

Ahead

  1. Mar 2027Primary completion: phase 1 study in Renal InsufficiencyNCT07946068
  2. Aug 2027Primary completion: phase 1 study in Hepatic ImpairmentNCT07872033
  3. Sep 2028Primary completion: phase 3 study in ObesityNCT07654374
  4. Sep 2028Primary completion: phase 3 study in ObesityNCT07654361

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07946068Renal Insufficiency · United States1Not yet recruitingMar 202716
NCT07872033Hepatic Impairment · United States1RecruitingAug 202736
NCT07654374Obesity · United States3RecruitingSep 20281,100
NCT07654361Obesity · United States3RecruitingSep 20283,600
NCT07400588Obesity · United States2CompletedSep 18, 202658
NCT06139055Healthy Volunteers · United States1Active, not recruitingMar 202470
NCT05893043Healthy Volunteers · United States1CompletedJun 28, 202318
NCT05762471Overweight · United States2CompletedApr 11, 2024142

How it is read

Names in the registry

  • “Aleniglipron”, 4 entries
  • “aleniglipron”, 3 entries
  • “GSBR-1290”, 3 entries
  • “GSBR-1290 (Capsule/Tablet)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.